Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Public Citizen sues FDA over Propecia side effects

By Brian Buntz | September 8, 2021

Public CitizenThe nonprofit watchdog group Public Citizen has filed a lawsuit on behalf of the Post-Finasteride Syndrome Foundation (PFSF), which, in 2017, petitioned the FDA to pull the hair loss drug Propecia (finasteride) from the market.

The lawsuit, which was filed in the U.S. District Court for the District of Columbia, asks the court to force FDA to issue a decision on PFSF’s petition within 30 days of the Court’s order.

Merck is the manufacturer of Propecia, which first won FDA approval for male pattern baldness in 1997. Propecia is a 5-alpha reductase inhibitor.

PFSF’s 2017 petition to FDA cites evidence of adverse events including depression and suicidal ideation.

The drug has also been linked to post-finasteride syndrome (PFS), which involves a constellation of adverse side effects.

The lawsuit cites PFS as a syndrome appearing in peer-reviewed studies that can afflict men for “​​years after they have stopped taking finasteride.”

Post-Finasteride Syndrome Foundation describes PFS as involving “persistent sexual, neurological, physical and mental adverse reactions in patients who have taken finasteride.”

Researchers are divided on the nature of the syndrome. A 2020 article in Neurobiology of Stress concluded that PFS is an “emerging clinical problem.” Conversely, another article published that same year in Fertility and Sterility asks whether PFS is “a real clinical condition caused by finasteride use.” Finally, a 2019 article in Skin Appendage Disorders concludes that the drug has “demonstrated both a high efficacy of treatment and a very favorable safety profile, establishing the drug as first-line treatment of male pattern hair loss.” It goes on to ask whether PFS is an “induced delusional disorder.”

Other studies have concluded that finasteride can have sexual and psychological side effects, including suicidal ideation in some men.

Regulatory bodies in Canada and Europe have added warnings about suicidal ideation and ideation to finasteride.

Finasteride first won FDA approval in 1992 as the Proscar, which is indicated at a 5-mg dose to treat symptomatic benign prostatic hyperplasia.

Propecia is a brand name for 1 mg of finasteride.

Demand for the drug has grown in recent years, and generic versions have been available since 2006. U.S. prescriptions have doubled from 2015 to 2020, according to the Post-Finasteride Syndrome Foundation lawsuit.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE